Lumos Pharma (LUMO) Stock Forecast, Price Target & Predictions
LUMO Stock Forecast
Lumos Pharma stock forecast is as follows: an average price target of $16.50 (represents a 319.85% upside from LUMO’s last price of $3.93) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LUMO Price Target
The average price target for Lumos Pharma (LUMO) is $16.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $7.00. This represents a potential 319.85% upside from LUMO's last price of $3.93.
LUMO Analyst Ratings
According to 3 Wall Street analysts, Lumos Pharma's rating consensus is 'Buy'. The analyst rating breakdown for LUMO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lumos Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | Jefferies | $7.00 | $4.46 | 56.95% | 78.12% |
| May 10, 2022 | Yasmeen Rahimi | Piper Sandler | $26.00 | $8.05 | 222.98% | 561.58% |
The latest Lumos Pharma stock forecast, released on Dec 08, 2022 by Jefferies company, set a price target of $7.00, which represents a 56.95% increase from the stock price at the time of the forecast ($4.46), and a 78.12% increase from LUMO last price ($3.93).
Lumos Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.93 | $3.93 | $3.93 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Lumos Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lumos Pharma's last price of $3.93. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 14, 2022 | Jefferies | - | Hold | Downgrade |
| May 10, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Lumos Pharma's last stock rating was published by Oppenheimer on May 15, 2024. The company gave LUMO a "Outperform" rating, the same as its previous rate.
Lumos Pharma Financial Forecast
Lumos Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $7.00K | $527.00K | $691.00K | $512.00K | $497.00K | - | $111.00K | $10.00K | $40.00K | $74.00K | $33.00K | $21.00K | $433.00K | $246.00K | - | $202.00K | $120.00K | $2.25M | $9.90M | $5.48M | $10.37M |
| Avg Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $6.67M | $166.67K | $265.00K | $300.00K | $10.00K | $225.40K | $365.17K | $222.40K | $114.33K | $66.67K | $18.50K | $107.26K | $9.70K | $25.00K | $2.60M | $35.79K | $34.57K | $250.00K | $225.50K | $101.00K | $-1.19M | $162.00K | $2.75M | $10.98M | $5.78M | $12.64M |
| High Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $6.67M | $166.67K | $265.00K | $300.00K | $10.00K | $225.40K | $365.17K | $222.40K | $114.33K | $66.67K | $18.50K | $128.71K | $11.64K | $49.36K | $5.13M | $42.95K | $41.49K | $493.58K | $270.60K | $199.41K | $-951.36K | $194.40K | $3.30M | $13.18M | $6.94M | $15.17M |
| Low Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $6.67M | $166.67K | $265.00K | $300.00K | $10.00K | $225.40K | $365.17K | $222.40K | $114.33K | $66.67K | $18.50K | $85.81K | $7.76K | $629.00 | $65.45K | $28.63K | $27.66K | $6.29K | $180.40K | $2.54K | $-1.43M | $129.60K | $2.20M | $8.78M | $4.63M | $10.11M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 11 | 12 | 10 | 5 | 10 | 15 | 6 | 14 | 6 | 15 | 9 | 9 | 10 | 8 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.03% | 1.44% | 3.11% | 4.48% | 7.45% | - | 1.03% | 1.03% | 1.60% | 0.03% | 0.92% | 0.61% | 1.73% | 1.09% | - | -0.17% | 0.74% | 0.82% | 0.90% | 0.95% | 0.82% |
Lumos Pharma's average Quarter revenue forecast for Dec 23 based on 2 analysts is $10.00K, with a low forecast of $10.00K, and a high forecast of $10.00K. LUMO's average Quarter revenue forecast represents a 42.86% increase compared to the company's last Quarter revenue of $7.00K (Sep 23).
Lumos Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 11 | 12 | 10 | 5 | 10 | 15 | 6 | 14 | 6 | 15 | 9 | 9 | 10 | 8 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-8.93M | $-9.64M | $-8.03M | $-9.22M | $-7.25M | - | $-7.71M | $-8.65M | $-6.86M | $-512.00K | $-6.60M | $-5.04M | $-7.49M | $-14.57M | $-1.91M | $-10.29M | $-14.14M | $-16.97M | $-17.96M | $-20.39M | $-16.37M |
| Avg Forecast | $-100.00K | $-100.00K | $-100.00K | $-100.00K | $-6.67M | $-166.67K | $-265.00K | $-300.00K | $-10.00K | $-225.40K | $-365.17K | $-222.40K | $-114.33K | $-66.67K | $-18.50K | $-7.44M | $-8.40M | $-25.00K | $-1.07M | $-7.15M | $-8.29M | $-9.09M | $-8.90M | $-2.37M | $-12.19M | $-19.08M | $-20.70M | $-19.92M | $-21.50M | $-19.96M |
| High Forecast | $-100.00K | $-100.00K | $-100.00K | $-100.00K | $-6.67M | $-166.67K | $-265.00K | $-300.00K | $-10.00K | $-225.40K | $-365.17K | $-222.40K | $-114.33K | $-66.67K | $-18.50K | $-5.95M | $-6.72M | $-629.00 | $-858.24K | $-5.72M | $-6.63M | $-7.27M | $-7.12M | $-1.90M | $-9.75M | $-15.27M | $-16.56M | $-15.94M | $-17.20M | $-15.97M |
| Low Forecast | $-100.00K | $-100.00K | $-100.00K | $-100.00K | $-6.67M | $-166.67K | $-265.00K | $-300.00K | $-10.00K | $-225.40K | $-365.17K | $-222.40K | $-114.33K | $-66.67K | $-18.50K | $-8.93M | $-10.08M | $-49.36K | $-1.29M | $-8.59M | $-9.95M | $-10.91M | $-10.68M | $-2.85M | $-14.63M | $-22.90M | $-24.84M | $-23.91M | $-25.80M | $-23.95M |
| Surprise % | - | - | - | - | - | - | - | - | - | 39.63% | 26.41% | 36.09% | 80.69% | 108.70% | - | 1.04% | 1.03% | 274.32% | 0.48% | 0.92% | 0.61% | 0.82% | 1.64% | 0.81% | 0.84% | 0.74% | 0.82% | 0.90% | 0.95% | 0.82% |
undefined analysts predict LUMO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lumos Pharma's previous annual EBITDA (undefined) of $NaN.
Lumos Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 11 | 12 | 10 | 5 | 10 | 15 | 6 | 14 | 6 | 15 | 9 | 9 | 10 | 8 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-8.30M | $-8.93M | $-6.66M | $-7.67M | $-6.95M | - | $-7.71M | $-8.67M | $-2.42M | $1.76M | $-5.35M | $340.00K | $-8.27M | $-14.55M | $-2.10M | $-10.57M | $-7.40M | $-17.31M | $-18.31M | $-20.63M | $-16.73M |
| Avg Forecast | $-4.65M | $-4.35M | $-4.49M | $-4.11M | $-2.73M | $-5.17M | $-9.52M | $-9.22M | $-9.23M | $-9.31M | $-8.90M | $-9.05M | $-7.56M | $-8.18M | $-7.99M | $-7.46M | $-8.41M | $-6.98M | $3.70M | $-5.81M | $559.75K | $-10.04M | $-8.89M | $-2.34M | $-12.52M | $-9.99M | $-21.11M | $-20.31M | $-21.76M | $-20.39M |
| High Forecast | $-4.65M | $-4.35M | $-4.49M | $-4.11M | $-2.73M | $-1.86M | $-9.52M | $-9.22M | $-8.68M | $-9.31M | $-8.90M | $-9.05M | $-7.56M | $-8.18M | $-7.99M | $-5.97M | $-6.73M | $1.87M | $4.44M | $-4.64M | $671.71K | $-8.03M | $-7.11M | $-1.87M | $-10.01M | $-8.00M | $-16.89M | $-16.25M | $-17.40M | $-16.31M |
| Low Forecast | $-4.65M | $-4.35M | $-4.49M | $-4.11M | $-2.73M | $-8.88M | $-9.52M | $-9.22M | $-10.09M | $-9.31M | $-8.90M | $-9.05M | $-7.56M | $-8.18M | $-7.99M | $-8.95M | $-10.09M | $-15.83M | $2.96M | $-6.97M | $447.80K | $-12.05M | $-10.67M | $-2.81M | $-15.02M | $-11.99M | $-25.34M | $-24.37M | $-26.11M | $-24.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.89% | 1.00% | 0.74% | 1.02% | 0.85% | - | 1.03% | 1.03% | 0.35% | 0.48% | 0.92% | 0.61% | 0.82% | 1.64% | 0.90% | 0.84% | 0.74% | 0.82% | 0.90% | 0.95% | 0.82% |
Lumos Pharma's average Quarter net income forecast for Dec 20 is $-6.98M, with a range of $-15.83M to $1.87M. LUMO's average Quarter net income forecast represents a -495.69% decrease compared to the company's last Quarter net income of $1.76M (Sep 20).
Lumos Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 11 | 12 | 10 | 5 | 10 | 15 | 6 | 14 | 6 | 15 | 9 | 9 | 10 | 8 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.89M | $4.15M | $4.36M | $4.49M | $3.92M | - | $3.62M | $4.56M | $4.63M | $5.16M | $4.15M | $3.33M | $6.68M | $8.28M | $9.31M | $5.43M | $7.59M | $7.91M | $8.29M | $7.91M | $8.90M |
| Avg Forecast | $4.27M | $4.27M | $4.27M | $4.27M | $284.39M | $7.11M | $11.30M | $12.80M | $426.58K | $9.62M | $15.58M | $9.49M | $4.88M | $2.84M | $789.17K | $4.58M | $413.87K | $1.07M | $110.91M | $1.53M | $1.47M | $10.66M | $9.62M | $4.31M | $-50.73M | $6.91M | $117.16M | $9.20M | $246.67M | $10.85M |
| High Forecast | $4.27M | $4.27M | $4.27M | $4.27M | $284.39M | $7.11M | $11.30M | $12.80M | $426.58K | $9.62M | $15.58M | $9.49M | $4.88M | $2.84M | $789.17K | $5.49M | $496.63K | $2.11M | $218.98M | $1.83M | $1.77M | $21.06M | $11.54M | $8.51M | $-40.58M | $8.29M | $140.59M | $11.04M | $296.00M | $13.02M |
| Low Forecast | $4.27M | $4.27M | $4.27M | $4.27M | $284.39M | $7.11M | $11.30M | $12.80M | $426.58K | $9.62M | $15.58M | $9.49M | $4.88M | $2.84M | $789.17K | $3.66M | $331.07K | $26.83K | $2.79M | $1.22M | $1.18M | $268.45K | $7.70M | $108.44K | $-60.88M | $5.53M | $93.73M | $7.36M | $197.33M | $8.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.40% | 0.27% | 0.46% | 0.92% | 1.38% | - | 0.79% | 11.02% | 4.34% | 0.05% | 2.72% | 2.26% | 0.63% | 0.86% | 2.16% | -0.11% | 1.10% | 0.07% | 0.90% | 0.03% | 0.82% |
Lumos Pharma's average Quarter SG&A projection for Dec 23 is $426.58K, based on 2 Wall Street analysts, with a range of $426.58K to $426.58K. The forecast indicates a -89.04% fall compared to LUMO last annual SG&A of $3.89M (Sep 23).
Lumos Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 11 | 12 | 10 | 5 | 10 | 15 | 6 | 14 | 6 | 15 | 9 | 9 | 10 | 8 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.04 | $-0.00 | $-0.81 | $-0.92 | $-0.83 | - | $-0.92 | $-0.99 | $-0.29 | $0.21 | $-0.65 | $0.16 | $-1.98 | $-3.51 | $-0.51 | $-2.52 | $-1.80 | $-4.23 | $-4.41 | $-6.21 | $-5.13 |
| Avg Forecast | $-0.57 | $-0.54 | $-0.55 | $-0.51 | $-0.34 | $-0.64 | $-1.17 | $-1.14 | $-1.14 | $-1.15 | $-1.10 | $-1.11 | $-0.93 | $-1.01 | $-0.99 | $-0.89 | $-1.03 | $-0.86 | $-0.65 | $-0.70 | $-0.82 | $-2.52 | $-2.43 | $-2.75 | $-3.66 | $-4.86 | $-6.61 | $-5.49 | $-0.77 | $-0.89 |
| High Forecast | $-0.57 | $-0.54 | $-0.55 | $-0.51 | $-0.34 | $-0.23 | $-1.17 | $-1.14 | $-1.07 | $-1.15 | $-1.10 | $-1.11 | $-0.93 | $-1.01 | $-0.99 | $0.24 | $0.28 | $0.23 | $0.17 | $0.19 | $0.22 | $0.67 | $0.65 | $0.73 | $-2.93 | $-3.89 | $-5.29 | $-4.39 | $-0.62 | $-0.71 |
| Low Forecast | $-0.57 | $-0.54 | $-0.55 | $-0.51 | $-0.34 | $-1.10 | $-1.17 | $-1.14 | $-1.24 | $-1.15 | $-1.10 | $-1.11 | $-0.93 | $-1.01 | $-0.99 | $-2.02 | $-2.34 | $-1.95 | $-1.46 | $-1.59 | $-1.87 | $-5.71 | $-5.51 | $-6.22 | $-4.39 | $-5.83 | $-7.93 | $-6.59 | $-0.92 | $-1.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.91% | 0.00% | 0.73% | 0.99% | 0.82% | - | 1.03% | 0.96% | 0.34% | -0.33% | 0.93% | -0.19% | 0.79% | 1.44% | 0.19% | 0.69% | 0.37% | 0.64% | 0.80% | 8.06% | 5.76% |
According to 10 Wall Street analysts, Lumos Pharma's projected average Quarter EPS for Dec 20 is $-0.86, with a low estimate of $-1.95 and a high estimate of $0.23. This represents a -510.48% decrease compared to LUMO previous annual EPS of $0.21 (Sep 20).
Lumos Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| LUMO | Lumos Pharma | $3.93 | $16.50 | 319.85% | Buy |
| STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
LUMO Forecast FAQ
Is Lumos Pharma a good buy?
Yes, according to 3 Wall Street analysts, Lumos Pharma (LUMO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of LUMO's total ratings.
What is LUMO's price target?
Lumos Pharma (LUMO) average price target is $16.5 with a range of $7 to $26, implying a 319.85% from its last price of $3.93. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lumos Pharma stock go up soon?
According to Wall Street analysts' prediction for LUMO stock, the company can go up by 319.85% (from the last price of $3.93 to the average price target of $16.5), up by 561.58% based on the highest stock price target, and up by 78.12% based on the lowest stock price target.
Can Lumos Pharma stock reach $6?
LUMO's average twelve months analyst stock price target of $16.5 supports the claim that Lumos Pharma can reach $6 in the near future.
What are Lumos Pharma's analysts' financial forecasts?
Lumos Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $7.4M (high $7.4M, low $7.4M), average EBITDA is $-7.398M (high $-7.398M, low $-7.398M), average net income is $-26.631M (high $-23.325M, low $-30.35M), average SG&A $315.6M (high $315.6M, low $315.6M), and average EPS is $-3.283 (high $-2.875, low $-3.741). LUMO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $400K (high $400K, low $400K), average EBITDA is $-400K (high $-400K, low $-400K), average net income is $-17.604M (high $-17.604M, low $-17.604M), average SG&A $17.06M (high $17.06M, low $17.06M), and average EPS is $-2.17 (high $-2.17, low $-2.17).
Did the LUMO's actual financial results beat the analysts' financial forecasts?
Based on Lumos Pharma's last annual report (Dec 2023), the company's revenue was $2.05M, beating the average analysts forecast of $822.97K by 149.22%. Apple's EBITDA was $-36.614M, beating the average prediction of $-823K by 4349.02%. The company's net income was $-34.034M, missing the average estimation of $-36.488M by -6.72%. Apple's SG&A was $16.57M, missing the average forecast of $35.11M by -52.80%. Lastly, the company's EPS was $-0.0042, missing the average prediction of $-4.498 by -99.91%. In terms of the last quarterly report (Sep 2023), Lumos Pharma's revenue was $7K, missing the average analysts' forecast of $225.4K by -96.89%. The company's EBITDA was $-8.932M, beating the average prediction of $-225K by 3862.73%. Lumos Pharma's net income was $-8.3M, missing the average estimation of $-9.313M by -10.88%. The company's SG&A was $3.89M, missing the average forecast of $9.62M by -59.51%. Lastly, the company's EPS was $-1.04, missing the average prediction of $-1.148 by -9.41%